<DOC>
	<DOC>NCT02204644</DOC>
	<brief_summary>A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control</brief_summary>
	<brief_title>The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. Men and women aged 1875 yearold 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 2 3. Philadelphia chromosomepositive chronic myeloid leukemia in chronic phase (Ph + CPCML) within 6 months of diagnosis 4. Adequate organ function 1. received TKIs drug treatment before enrollment 2. Central nervous system leukemia 3. Previous antiCML therapy over two weeks (hydroxyurea, except anagrelide) or surgery (including hematopoietic stem cell transplantation) 4. Cardiac dysfunction 5. Previous splenectomy 6. History of congenital or acquired bleeding disorders unrelated to CML 7. Previous malignancy except CML 8. Acute or chronic liver or severe kidney disease unrelated to CML 9. Pregnant, breastfeeding, child bearing potential but failed to take effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>